Skip to main content

Table 4 Treatment-related adverse events

From: Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination

n (%) TACE plus apatinib plus camrelizumab (n = 80)
All grade Grade ≥ 3
Hand-foot skin reaction 33 (41.3) 5 (6.3)
Hypertension 35 (43.8) 6 (7.5)
Fatigue 16 (20.0) 2 (2.5)
Mouth ulcers 5 (6.3) 0 (0)
Proteinuria 25 (31.3) 1 (1.3)
Rash 11 (13.8) 0 (0)
Hoarseness 4 (5.0) 0 (0)
Gingival hamorrhage 3 (3.8) 0 (0)
Decreased appetite 14 (17.5) 0 (0)
Diarrhoea 13 (16.3) 2 (2.5)
Hypothyroidism 15 (18.8) 0 (0)
Hyperthyroidism 3 (3.8) 0 (0)
RCCEP 16 (20.0) 0 (0)
Myocarditis 3 (3.8) 1 (1.3)
Haemorrhage, upper GI 3 (3.8) 0 (0)
  1. RCCEP reactive cutaneous capillary endothelial proliferation, GI gastrointestinal tract